A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular

Next Previous
Trial Profile

A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs Lenvatinib (Primary) ; Nivolumab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 02 Feb 2018 Status changed from planning to recruiting.
    • 09 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top